Lung Cancer

Secondhand Smoke and Cancer (Fact Sheet)

Secondhand Smoke and Cancer (Fact Sheet)

This fact sheet reviews secondhand smoke composition, links between secondhand smoke and cancer, and secondhand smoke emitted from electronic cigarettes.

Patients' Satisfaction With Chemotherapy Influences Health-Related Quality of Life in Advanced Thoracic Cancer

Patients' Satisfaction With Chemotherapy Influences Health-Related Quality of Life in Advanced Thoracic Cancer

By

Dutch researchers sought to determine the association between satisfaction with treatment and HRQoL scores among patients with locally advanced or metastatic thoracic cancer receiving pemetrexed.

Healthcare Professionals Weigh In on Chemotherapy Use In Malignant Pleural Mesothelioma

Healthcare Professionals Weigh In on Chemotherapy Use In Malignant Pleural Mesothelioma

By

A survey of healthcare professionals sought to determine their perspectives on aspects of treatment decision-making related to administration of chemotherapy in eligible patients with malignant pleural mesothelioma.

Malignant Pleural Effusion Interventions: What Matters Most to the Patient?

Malignant Pleural Effusion Interventions: What Matters Most to the Patient?

By

Patients with malignant pleural effusion may care more about relieving symptoms such as dyspnea as opposed to achieving pleurodesis.

Counseling on the Dangers of Vaping

Counseling on the Dangers of Vaping

By

How can nurses caring for smokers counsel patients on quitting smoking when many are using vaping as an alternative to cigarettes?

Chemoradiotherapy Outcomes Associated With Stage of Small Cell Lung Cancer

Chemoradiotherapy Outcomes Associated With Stage of Small Cell Lung Cancer

By

A secondary analysis of data from the CONVERT trial compared survival outcomes after chemoradiotherapy for patients with stage I-II vs patients with stage III disease.

Lung Cancer-Specific Distress Screening Tool Not Needed But Has Potential Benefit

Lung Cancer-Specific Distress Screening Tool Not Needed But Has Potential Benefit

By

Using focus groups, researchers evaluated patient-reported psychosocial consequences of lung cancer to determine if a lung cancer-specific distress screening instrument would benefit these patients.

Immunotherapy Side Effects May Be More Common Than Thought

Immunotherapy Side Effects May Be More Common Than Thought

Higher rates of adverse events observed for immune checkpoint inhibitors in real-world settings, compared to clinical trials.

Safe to Administer B12 Supplementation, Pemetrexed Infusions for Lung Cancers on Same Day

Safe to Administer B12 Supplementation, Pemetrexed Infusions for Lung Cancers on Same Day

By

Mean changes in hematologic indices found similar regardless of same-day or prior administration of B12 supplementation in patients receiving pemetrexed for NSCLC or pleural mesothelioma.

Real-World Prevalence of AEs With Immune Checkpoint Inhibitors for NSCLC Higher Than Reported in Trials

Real-World Prevalence of AEs With Immune Checkpoint Inhibitors for NSCLC Higher Than Reported in Trials

By

Study suggests irAEs with PD-L1 therapy for NSCLC occur more frequently in real-world vs clinical trial populations.

Smoking, Lung Cancer Mortality Decline But Their Numbers Will Remain Significant

Smoking, Lung Cancer Mortality Decline But Their Numbers Will Remain Significant

By

Trends are showing a decline in number of smokers and lung cancer mortality rate; however, simulation models show that the number of smokers and lung cancer-related deaths will still be high for 2015 to 2065.

E-cigarette Use Increasing Among Younger, Tobacco-Naïve Adults

E-cigarette Use Increasing Among Younger, Tobacco-Naïve Adults

By

A review of data from the Behavioral Risk Factor Surveillance System revealed that e-cigarette use among adult smokers has declined, but among nonsmokers 18 to 24 years old, use has increased in the same period.

Use of Corticosteroids With PD-1 or PD-L1 Inhibitors Associated With Poorer Outcomes in NSCLC

Use of Corticosteroids With PD-1 or PD-L1 Inhibitors Associated With Poorer Outcomes in NSCLC

By

A retrospective study of patients with NSCLC from 2 cancer centers demonstrates that concurrent use of corticosteroids with PD-1 or PD-L1 inhibitors at baseline decreases progression-free and overall survival for these patients.

Early Checkpoint Inhibition With Cytotoxic Chemotherapy Improves OS, PFS in Extensive-Stage SCLC

Early Checkpoint Inhibition With Cytotoxic Chemotherapy Improves OS, PFS in Extensive-Stage SCLC

By

In this randomized, double-blind, placebo-controlled study, researchers sought to determine the effect of including a checkpoint inhibitor in induction therapy for patients with extensive-stage small cell lung cancer.

Aggressive EOL Care Negatively Impacts Care Quality, Health Costs in Metastatic Lung Cancer

Aggressive EOL Care Negatively Impacts Care Quality, Health Costs in Metastatic Lung Cancer

By

Researchers determined that aggressive care at the end of life (EOL) leads to diminished quality of life, poor quality of care, and increased costs for patients with advanced lung cancer.

Influence of Surgical Options for Early-Stage Lung Cancer on Opioid Use

Influence of Surgical Options for Early-Stage Lung Cancer on Opioid Use

By

A research letter presents results of a study on opioid use among patients in the SEER database who underwent open resection vs VATS for non-small cell lung cancer.

SCOOPs Program Improves Patient Experience, Reduces Costs

SCOOPs Program Improves Patient Experience, Reduces Costs

By

Researchers report on the effectiveness results of the Supportive Care of Oncology Patients (SCOOPs) Program were presented at the 2018 ASCO Quality Care Symposium.

Lobectomy vs SBRT: A Comparison of Prognoses and Survival for Early-Stage NSCLC

Lobectomy vs SBRT: A Comparison of Prognoses and Survival for Early-Stage NSCLC

By

A comparison study demonstrated the difference in survival rates between lobectomy and SBRT for early-stage non-small cell lung cancer.

Prophylactic Cranial Irradiation in Small-Cell Lung Cancer: Update on Patient Selection, Efficacy and Outcomes

Prophylactic Cranial Irradiation in Small-Cell Lung Cancer: Update on Patient Selection, Efficacy and Outcomes

[Lung Cancer: Targets and Therapy] This review presents a summary and update of the latest evidence for patient selection, efficacy and outcome of primary treatment, prophylactic cranial irradiation (PCI) in the treatment of patients with SCLC.

Preventative Medications Unnecessarily Prescribed to EOL Patients With Lung Cancer

Preventative Medications Unnecessarily Prescribed to EOL Patients With Lung Cancer

By

In a retrospective study conducted in the United States and the United Kingdom, researchers evaluated the prescribing of preventative medications in patients with lung cancer discharged from hospital at the end of life.

Using Palliative Care to Improve Lung Cancer Outcomes in Veterans at Risk of Suicide

Using Palliative Care to Improve Lung Cancer Outcomes in Veterans at Risk of Suicide

By

In a review of data from more than 20,000 veterans, researchers determined the effects of palliative care on suicide rates among veterans with advanced lung cancer.

Pembrolizumab Combination for Metastatic NSCLC Upgraded to Full FDA Approval

Pembrolizumab Combination for Metastatic NSCLC Upgraded to Full FDA Approval

By

FDA upgraded the approval of pembrolizumab in combination with pemetrexed and platinum chemotherapy as a first-line treatment for patients with metastatic, nonsquamous NSCLC with no EGFR or ALK genomic tumor aberrations from accelerated to regular approval.

Oral Hydration Effectively Reduced Risk of Nephrotoxity After Cisplatin

Oral Hydration Effectively Reduced Risk of Nephrotoxity After Cisplatin

By

A single-center retrospective study determined the safety of IV hydration before and oral hydration after cisplatin therapy to prevent nephrotoxicity in patients with lung cancer vs IV hydration both before and after therapy.

New PDL1 Inhibitors for Non-small Cell Lung Cancer: Focus on Pembrolizumab

New PDL1 Inhibitors for Non-small Cell Lung Cancer: Focus on Pembrolizumab

[OncoTargets and Therapy] Evidence increasingly suggests that pembrolizumab has a significant role in first- and second-line therapy for NSCLC. This review presents the results of previous and ongoing studies and discusses biomarkers that can potentially identify eligible candidates for treatment with the PD-L1 inhibitor.

Mortality Rates for Lung Cancer Likely to Surpass Breast Cancer Among Women by 2030

Mortality Rates for Lung Cancer Likely to Surpass Breast Cancer Among Women by 2030

By

Screening practices and smoking habits are expected to have a significant impact on mortality rates for lung cancer and breast cancer among women in high-income countries.

Link Between Asbestos-Free Talcum Powder and Cancer Unclear

Link Between Asbestos-Free Talcum Powder and Cancer Unclear

Studies conducted in people have mixed results, with some indication of increased risk of ovarian cancer.

Lung Cancer Screening: Effective Models for Selecting the Most Candidates at Highest Risk

Lung Cancer Screening: Effective Models for Selecting the Most Candidates at Highest Risk

By

Four of 9 lung cancer screening models were shown to effectively select the most appropriate candidates for low-dose CT lung cancer screening among US ever-smokers.

Lung Cancer: What Nurse Navigators Need to Know in 2018

Lung Cancer: What Nurse Navigators Need to Know in 2018

By

There have been many recent changes in lung cancer, including updated early detection possibilities and changes in diagnostic procedures, reporting, and treatment options. These are reviewed in a presentation at the 2018 ONA Navigation Summit.

Radiation-Induced Esophagitis: A Common, Debilitating Clinical Challenge in Thoracic Radiotherapy

Radiation-Induced Esophagitis: A Common, Debilitating Clinical Challenge in Thoracic Radiotherapy

By

A review of current options and ongoing trials for managing ARIE, a common esophageal adverse effect caused by radiotherapy to the thoracic region for lung, breast, or head and neck cancers, or lymphoma.

Ado-trastuzumab Emtansine Effective in HER2 Amplified Non-breast, Non-gastric Cancers

Ado-trastuzumab Emtansine Effective in HER2 Amplified Non-breast, Non-gastric Cancers

By

Study results presented at 2018 ASCO Annual Meeting demonstrated effectiveness of ado-trastuzumab emtansine in non-breast non-gastric HER2-amplified cancers.

Sign Up for Free e-newsletters



Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Genitourinary Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Rare Cancers Regimens
Skin Cancer Regimens Drugs